Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced April through May 2014.
Idera Pharmaceuticals Inc. (toll-like receptor (TLR) antagonists for autoimmune diseases and B-cell lymphomas) signed on Abbott Laboratories Inc. to develop a companion in vitro diagnostic for use with its Phase II IMO8400 B-cell lymphoma program. (May)
The Big Pharma will apply polymerase chain reaction (PCR) technology to detect, with high sensitivity and specificity, the MYD88 L265P...
Bristol Myers Squibb executive Doxie Jordan discusses his path to global commercial leadership and the principles guiding pharmaceutical market strategy
Devika Wood, CEO of Brain+, explains the importance of developing health tech solutions for dementia and the growing need to both raise awareness and improve overall access to nondrug interventions like CST.
In a challenging funding environment for biopharma, strategic dealmaking has become a critical growth engine. In Vivo explores what it truly takes to navigate high-stakes acquisitions and partnerships, drawing on insights from seasoned industry leaders.
